Cardiac Science Powerheart
This article was originally published in The Gray Sheet
Executive Summary
Next-generation automated external defibrillator (AED) for public access commences worldwide shipping, following 510(k) clearance announced Feb. 5. Device incorporates the firm's RHYTHMx technology used in the Powerheart CRM hospital bedside version (1"The Gray Sheet" Dec. 10, 2001, p. 21). Marketing is being conducted by a 36-person direct AED U.S. sales force and distributors in over 40 countries. Addressing an AED market expected to reach $650 mil. by 2006, the device continuously monitors a victim's heart rhythm after revival and eliminates the need for the rescuer to determine if the victim has a pulse prior to attaching the device...
You may also be interested in...
Cardiac Science Powerheart Approval Revitalizes Stock In November
The possibility of the next-generation Powerheart bedside monitor-defibrillator emerging as a standard fixture in the acute-care setting helped to almost double Cardiac Science's stock price for November
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.